Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

World Journal of Surgery

Volumn 38, Issue 8, 2014, Pages 2046-2051

  Hamai, Yoichi ^a   Hihara, Jun ^a   Taomoto, Junya ^a   Yamakita, Ichiko ^a   Ibuki, Yuta ^a   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; BLOOD; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903781218     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-014-2486-2     Document Type: Article

References (32)

1. Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681-692
2. Van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084
3. Tepper J, Krasna MJ, Niedzwiecki D et al (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086-1092
4. Walsh TN, Noonan N, Hollywood D et al (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467 (Pubitemid 26269945)
5. Berger AC, Farma J, Scott WJ et al (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330-4337 (Pubitemid 46207006)
6. Brücher BL, Stein HJ, Zimmermann F et al (2004) Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 30:963-971 (Pubitemid 39462527)
7. Reynolds JV, Muldoon C, Hollywood D et al (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245:707-716 (Pubitemid 46684100)
8. Dittrick GW, Weber JM, Shridhar R et al (2012) Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol 19:1678-1684
9. Li SH, Huang EY, Lu HI et al (2012) Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 144:1352-1359
10. Duong C, Greenawalt DM, Kowalczyk A et al (2007) Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol 14:3602-3609 (Pubitemid 350160118)
11. Maher SG, Gillham CM, Duggan SP et al (2009) Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg 250:729-737
12. Yi Y, Li B, Sun H et al (2010) Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Tumour Biol 31:333-340
13. Yasuda K, Sunami E, Kawai K et al (2012) Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. J Gastrointest Cancer 43:236-243
14. Kitayama J, Yasuda K, Kawai K et al (2010) Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 5:47
15. Sato H, Tsubosa Y, Kawano T (2012) Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg 36:617-622
16. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. John & Sons, New York
17. Nozoe T, Kohno M, Iguchi T et al (2012) The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today 42:532-535
18. Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nippon Geka Gakkai Zasshi 85:1001-1005 (in Japanese; English abstract)
19. Hihara J, Yoshida K, Hamai Y et al (2007) Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res 27:2597-2603 (Pubitemid 47227971)
20. Emi M, Hihara J, Hamai Y et al (2012) Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol 69:1499-1505
21. Japan Esophageal Society (2009) Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 6:71-94
22. Zhao KL, Liu G, Jiang GL et al (2006) Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy: a secondary analysis of three consecutive clinical phase III trials. Clin Oncol 18:621-627 (Pubitemid 44309261)
23. Rades D, Golke H, Schild SE et al (2008) The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation. Int J Radiat Oncol Biol Phys 71:152-159 (Pubitemid 351491394)
24. Zenda S, Hironaka S, Boku N et al (2008) Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 21:195-200 (Pubitemid 351593920)
25. Valencia Julve J, Alonso Orduña V, Escó Barón R et al (2006) Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol 8:22-30
26. Langendijk H, de Jong J, Wanders R et al (2003) The importance of pre-treatment haemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol 67:321-325 (Pubitemid 36831086)
27. Dunst J, Kuhnt T, Strauss HG et al (2003) Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56:778-787 (Pubitemid 36677372)
28. Kim JH, Lee JM, Ryu KS et al (2011) The prognostic impact of duration of anemia during chemotherapy in advanced epithelial ovarian cancer. Oncologist 16:1154-1161
29. Varlotto J, Stevenson MA (2005) Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63:25-36 (Pubitemid 41583539)
30. Adamson JW (2008) The anemia of inflammation/malignancy: mechanisms and management. Hematology 2008:159-165
31. Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243-259 (Pubitemid 34044509)
32. Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9:31-40 (Pubitemid 39658343)